Skip to search formSkip to main contentSkip to account menu

KRAS NP_004976.2:p.G12C

Known as: KRAS p.G12C, KRAS G12C, KRAS NP_004976.2:p.Gly12Cys 
A change in the amino acid residue at position 12 in the GTPase KRas protein where glycine has been replaced by cysteine.
National Institutes of Health

Related topics

Related topics

2 relations
KRAS NM_004985.3:c.34_36delGGTinsTGCKras gene mutation

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Current therapy of KRAS-mutant lung cancer
KRAS mutations are the most frequent gain-of-function alterations in patients with lung adenocarcinoma (LADC) in the Western… 
2020
2020
Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients
The KRAS mutation is the second most common genetic variant in Chinese non-small cell lung cancer (NSCLC) patients. At the 2019th… 
Review
2020
Review
2020
Current therapy of advanced colorectal cancer according to RAS/RAF mutational status
Colorectal cancer is a clinically and molecularly heterogeneous disease. Currently, extended RAS and BRAF mutation testing is… 
Review
2019
Review
2019
Progress in targeting RAS with small molecule drugs.
RAS proteins have traditionally been deemed undruggable, as they do not possess an active site to which small molecules could… 
2018
2018
Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C
Activating mutations in RAS genes are associated with approximately 20% of all human cancers. New targeted therapies show… 
Highly Cited
2017
Highly Cited
2017
Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C.
2017
2017
KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry.
Review
2016
Review
2016
Selective Targeting of the KRAS G12C Mutant: Kicking KRAS When It's Down.
Highly Cited
2013
Highly Cited
2013
KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma
KRAS mutations define a clinically distinct subgroup of lung adenocarcinoma patients, characterized by smoking history… 
Highly Cited
2013
Highly Cited
2013
Molecular Characterization of Gallbladder Cancer using Somatic Mutation Profiling
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)